George Ludwig
Corporate Officer/Principal bij ConPharm Anstalt
Profiel
Mr. Georg Ludwig is Managing Limited Partner at HighTech Private Equity GmbH
George Ludwig has been a Managing Director of ConPharm Anstalt since 2005 and a Director of Lorus Therapeutics, Inc. since September 2006.
Previously, he was a Managing Director of HighTech Private Equity from 2000 to 2004.
Actieve functies van George Ludwig
| Bedrijven | Functie | Begin |
|---|---|---|
| ConPharm Anstalt | Corporate Officer/Principal | 01-01-2005 |
Eerdere bekende functies van George Ludwig
| Bedrijven | Functie | Einde |
|---|---|---|
High Tech Private Equity GmbH
 High Tech Private Equity GmbH Investment ManagersFinance High Tech Private Equity GmbH (HTPE) is a leading German private equity firm controlled by Triginta Capital Group GmbH (formerly AVIDA Equity Partners) and DEWB AG. Established in 1999 and based in Düsseldorf with an office in Liechtenstein, HTPE invests in rapidly growing technology companies and manages the High Tech Beteiligungen fund, backed by institutional investors including German pension funds, banks and insurance companies. | Corporate Officer/Principal | 01-01-2004 |
| APTOSE BIOSCIENCES INC. | Directeur/Bestuurslid | 03-03-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| ConPharm Anstalt | |
High Tech Private Equity GmbH
High Tech Private Equity GmbH Investment ManagersFinance High Tech Private Equity GmbH (HTPE) is a leading German private equity firm controlled by Triginta Capital Group GmbH (formerly AVIDA Equity Partners) and DEWB AG. Established in 1999 and based in Düsseldorf with an office in Liechtenstein, HTPE invests in rapidly growing technology companies and manages the High Tech Beteiligungen fund, backed by institutional investors including German pension funds, banks and insurance companies. | Finance |
